Management of HBV in immunocompromised patients

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 182-187

  Pol, Stanislas ^a  

^a INSERM   (France)

Author keywords

Hepatitis B infection; Hepatitis B virus nucleos(t)ide analogues; Hepatitis B virus vaccination; Immune deficiency; Pre emptive therapy

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS PROTEIN;

DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; FIBROSING CHOLESTATIC HEPATITIS; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER FIBROSIS; LIVER TRANSPLANTATION; LYMPHOCYTOTOXICITY; MIXED INFECTION; PATHOLOGY; REVIEW; VIRUS LOAD;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; RISK FACTORS; TREATMENT OUTCOME;

EID: 84872050040     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12055     Document Type: Review

References (32)

1. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006; 25: 3823-33. Review.
2. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
3. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49(Suppl. 5): S156-65.
4. Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 554-7.
5. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-11.
6. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
7. Lau JY, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102: 956-62.
8. Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 3442-9.
9. Dandri M, Locarnini S. New insight in the pathobiolgy of hepatitis B virus infection. Gut 2012; 61(Suppl. 1): i6-17.
10. Urata Y, Uesato R, Tanaka D, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 16-23.
11. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5.
12. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8.
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
14. EASL Clinical Practice Guidelines. Management of chronic hepatitis B. J Hepatol 2012; 57: 167-85.
15. Barclay S, Pol S, Mutimer D, et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol 2008; 41: 243-54.
16. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008; 28: 28-38. Epub 2007 Nov 1. Review.
17. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28 Review. Erratum in: Ann Intern Med. 2009 May 5;150(9):657-8.
18. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324-30.
19. Hui CK, Bowden S, Jackson K, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005; 105: 2616-7.
20. Kohrt HE, Ouyang DL, Keeffe EF. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006; 24: 1003-16.
21. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-9.
22. Droz A, Gilardin L, Cacoub P, et al. Management of hepatitis B virus reactivation in patients with systemic inflammatory disease. Submitted for publication 2012.
23. Terrier B, Pol S, Thibault V, Gottenberg JE, Cacoub P. Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm. Rev Med Intern 2012; 33: 4-12.
24. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712.
25. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77: 859-64.
26. Vallet-Pichard A, Fontaine H, Mallet V, Pol S. Viral hepatitis in solid organ transplantation other than liver. J Hepatol 2011; 55: 474-82.
27. Ahn HJ, Kim MS, Kim YS, et al. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J Med Virol 2007; 79: 1655-63.
28. Cosconea S, Fontaine H, Méritet JF, et al. Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol 2012; 57: 55-60 Epub 2012 Mar 10.
29. Berger A, Preiser W, Kachel HG, Sturmer M, Doerr HW. HBV reactivation after kidney transplantation. J Clin Virol 2005; 32: 162-5.
30. Konopnicki D, Mocroft A, De DS, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy. AIDS 2005; 19: 593-601.
31. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19: 221-40.
32. Piroth L, Mahy S, Pol S, et al., et al. Current management and recommendations on hepatitis B therapy in HIV-coinfected patients. Hepatol Int 2011; PMID: 21761222.